Systemic vs Local Inflammation: Choosing the Right Therapeutic Delivery Strategy

The clinical burden of chronic inflammation is a primary driver of global morbidity, affecting millions of human patients and companion animals. Musculoskeletal disorders, including osteoarthritis (OA), rheumatoid arthritis (RA), and back pain, affect approximately 1.71 billion people worldwide and remain the leading cause of disability globally. Back pain alone affects an estimated 619 million while OA affects an estimated 595 million. These conditions are now among the leading causes of disability globally [1][2].

Conventional pharmacological strategies frequently require a direct trade-off between systemic toxicity and localized efficacy. This clinical friction has catalyzed a paradigm shift toward identifying a safe, natural anti-inflammatory alternative capable of modulating the immune system without the toxic side effects. While cannabidiol (CBD) offers clear therapeutic promise, its utility is severely limited by poor water solubility. Trait Biosciences has engineered a groundbreaking technology that transforms lipophilic cannabinoids into truly water-soluble, highly bioavailable ingredients.

Understanding Systemic and Local Inflammation

Inflammation may occur throughout the body or remain concentrated in a specific area [5]. Systemic inflammation involves broad immune activation and may contribute to conditions such as autoimmune disease, inflammatory arthritis, metabolic disorders, and chronic pain syndromes. On the other hand, local inflammation occurs in a defined tissue or region. Examples include knee OA, tendon irritation, muscle injury, back pain, or skin inflammation. In these cases, treatment may be most effective when the active ingredient reaches the affected tissue directly [3].

This distinction matters because the best treatment strategy depends not only on the condition but also on where the inflammation is occurring. A medication that circulates throughout the body may be useful for widespread inflammation, while a topical or targeted therapy may be better suited for localized pain or joint symptoms.

Current Approaches to Inflammation Management

Non-steroidal anti-inflammatory drugs, or NSAIDs, remain among the most common treatments for inflammation. These include ibuprofen, naproxen, diclofenac, and celecoxib. NSAIDs work mainly by blocking cyclooxygenase enzymes, which help produce prostaglandins involved in pain, fever, and inflammation [4][5].

Systemic NSAIDs can be effective for many inflammatory conditions, but long-term or frequent use carries important risks. These include stomach ulcers, GI bleeding, kidney impairment, fluid retention, and cardiovascular complications. These risks are especially important in older adults in people with heart disease, kidney disease, or a history of peptic ulcer disease (PUD) [6][7].

Topical NSAIDs were developed to reduce these risks. By applying medication directly to the affected area, topical formulations can deliver high local concentrations while limiting systemic exposure. Clinical evidence supports topical diclofenac and ketoprofen for acute sprains, strains, and OA of the hand and knee [8][9]. However, topical treatments also have limitations. They are most useful for accessible, superficial joints and soft tissues. They may not adequately treat deep inflammation or widespread inflammatory disease. Their effectiveness also depends on formulation quality, skin penetration, application site, and individual patient factors.

These limitations have increased interest in targeted delivery strategies that improve how pharmaceutical ingredients reach the tissues where they are needed.

Therapeutic Potential of CBD for Inflammation

Research demonstrates that CBD coordinates its biological response by interacting with the endocannabinoid system to regulate immune responses, dampening the release of pro-inflammatory cytokines like TNF-α and IL-6 while reducing cellular damage triggered by oxidative stress. This multi-pathway action positions CBD as an emerging option for managing both human joint discomfort and canine mobility issues [10][11].

The main obstacle for CBD is bioavailability. Traditional oral CBD has an estimated bioavailability of only 6—20%. Much of the dose may be lost because CBD is highly lipophilic, poorly water-soluble, and extensively metabolized in the liver before reaching systemic circulation [12][13]. Achieving a therapeutic dose requires excessive oil-based suspensions, which can cause gastrointestinal distress and inconsistent clinical outcomes in real-world use.

Water-Soluble Cannabidiol and the Trait Biosciences Solution

To resolve these delivery limitations, Trait Biosciences has introduced a remarkable proprietary platform. Unlike the typical water-compatible formulations, such as nanoemulsions or suspensions, that merely disperse microscopic oil droplets, Trait Biosciences had developed a truly water-soluble compound called CBD82S (Cannabildyl diglucoside). Using advanced enzymatic processes, Trait Biosciences appends glucose molecules directly to the CBD skeleton to yield a highly pure (>97%), free-flowing white powder. This structural change eliminates the need for surfactant emulsifiers or oils, allowing the compound to dissolve completely in water.

The physiological implications of this glycosylation are profound, demonstrating clear pharmacokinetic superiority. In fact, in tissue studies, Trait Biosciences’ water-soluble compound demonstrated 300 times faster intestinal permeation at one hour, 10 times higher oral epithelial transport at 40 minutes, and 100 times faster transdermal skin penetration over six hours compared to conventional CBD isolate.

Furthermore, in vivo testing conducted by Trait Biosciences highlights the health advantages of Trait’s technology. In preclinical testing, CBD82S generated a 3.7 fold greater upregulation of the crucial anti-inflammatory gene IL-10 compared to standard CBD-isolate. Topical administration of CBD82S in rats achieved 2.5 times higher accumulation of CBD in brain tissue, verifying robust blood-brain barrier penetration and systemic exposure. In canine and feline home surveys, animals receiving topical CBD82S experienced a significant reduction in joint pain and a marked improvement in mobility by Day 14. Additionally, mouse RFID models showed that oral CBD82S significantly decreased locomotor activity, indicating a robust, rapid-acting reduction in anxiety.

Evidence Gaps in Cannabinoid Therapy

While these preclinical and pilot outcomes are highly encouraging, scientific rigor demands an acknowledgement of existing evidence gaps. Currently, the clinical literature lacks long-term, large-scale human clinical trials evaluating water-soluble cannabinoids specifically for inflammation in the body. To address these gaps, Trait Biosciences has initiated and planned a clinical development pipeline, which will validate the transition of CBD82S from an innovative ingredient to a clinically proven standard for addressing what causes inflammation in the body.

Conclusion

Traditional anti-inflammatory approaches present clear therapeutic trade-offs, forcing patients to accept systemic risks or tolerate localized delivery barriers. CBD offers a safe alternative to standard anti-inflammatory supplements, but its performance has long been restricted by its lipophilic nature. By engineering CBD82S, Trait Biosciences has solved this delivery bottleneck, developing a highly stable, bioavailable, and water-soluble cannabinoid that drastically outperforms conventional CBD in tissue transport and therapeutic stability. This innovative platform is uniquely positioned to redefine precision delivery strategies for both systemic and local inflammation.

References

1. Key facts and figures – Global Alliance for Musculoskeletal Health. (2013, January 4). Global Alliance for Musculoskeletal Health – Keep People Moving. https://gmusc.com/key-facts-and-figures/
2. World Health Organization. (2022). Musculoskeletal health. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions
3. Klyne DM, Barbe MF, James G, Hodges PW. Does the Interaction between Local and Systemic Inflammation Provide a Link from Psychology and Lifestyle to Tissue Health in Musculoskeletal Conditions? Int J Mol Sci. 2021 Jul 7;22(14):7299. doi: 10.3390/ijms22147299. PMID: 34298917; PMCID: PMC8304860.
4. Ghlichloo, I., & Gerriets, V. (2023). Nonsteroidal anti-inflammatory drugs (nsaids). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547742/
5. Tsoupras A, Gkika DA, Siadimas I, Christodoulopoulos I, Efthymiopoulos P, Kyzas GZ. The Multifaceted Effects of Non-Steroidal and Non-Opioid Anti-Inflammatory and Analgesic Drugs on Platelets: Current Knowledge, Limitations, and Future Perspectives. Pharmaceuticals (Basel). 2024 May 14;17(5):627. doi: 10.3390/ph17050627. PMID: 38794197; PMCID: PMC11124379.
6. Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022 Mar;21(3):373-384. doi: 10.1080/14740338.2021.1965988. Epub 2021 Aug 18. PMID: 34376069.
7. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010 Nov;26(6):611-7. doi: 10.1097/MOG.0b013e32833e91eb. PMID: 20948372.
8. Bhat C, Rosenberg H, James D. Topical nonsteroidal anti-inflammatory drugs. CMAJ. 2023 Sep 18;195(36):E1231. doi: 10.1503/cmaj.230578. PMID: 37722741; PMCID: PMC10506512.
9. Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 Jun 11;2015(6):CD007402. doi: 10.1002/14651858.CD007402.pub3. PMID: 26068955; PMCID: PMC6426435.
10. Meissner, H., & Cascella, M. (2020). Cannabidiol (CBD). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK556048/
11. Lowin, T., Tingting, R., Zurmahr, J., Classen, T., Schneider, M., & Pongratz, G. (2020). Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death & Disease, 11(8). https://doi.org/10.1038/s41419-020-02892-1
12. Paczkowska-Walendowska, M., Piotr Trzaskoma, Aleksandra Dziopa, Arash Moeini, Michał Soczawa, Zbigniew Krasiński, & Judyta Cielecka-Piontek. (2025). Innovative Strategies to Enhance the Bioavailability of Cannabidiol: Nanotechnology and Advanced Delivery Systems. Pharmaceuticals, 18(11), 1637–1637. https://doi.org/10.3390/ph18111637
13. Franco, V., Gershkovich, P., Perucca, E., & Bialer, M. (2020). The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical Pharmacokinetics, 59(12), 1493–1500. https://doi.org/10.1007/s40262-020-00931-w